These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 15363049)

  • 1. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
    Wang AY; Li PK; Lui SF; Sanderson JE
    Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodialysis-associated hypertension: pathophysiology and therapy.
    Hörl MP; Hörl WH
    Am J Kidney Dis; 2002 Feb; 39(2):227-44. PubMed ID: 11840363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Left ventricular hypertrophy in chronic kidney disease].
    Paoletti E; Cannella G
    G Ital Nefrol; 2006; 23(6):560-8. PubMed ID: 17173262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
    Plante E; Lachance D; Beaudoin J; Champetier S; Roussel E; Arsenault M; Couet J
    Circ Heart Fail; 2009 Jan; 2(1):25-32. PubMed ID: 19808312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease.
    Sica DA; Gehr TW
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):247-54. PubMed ID: 12584668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
    Dahlöf B
    J Hypertens Suppl; 1993 Apr; 11(3):S29-35. PubMed ID: 8315516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors].
    He H; Li LM; Cao WH; Liu MZ; Sun NL; Lü J; Hu YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep; 25(9):756-60. PubMed ID: 15555355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ACE inhibition: mechanisms of cardioprotection in heart hypertrophy].
    Motz W; Strauer BE
    Klin Wochenschr; 1991; 69 Suppl 24():39-43; discussion 43-4. PubMed ID: 1830911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left-ventricular hypertrophy and coronary artery disease.
    Pierdomenico SD
    Am J Hypertens; 2007 Oct; 20(10):1036-7. PubMed ID: 17903684
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM
    Am J Med; 2008 Aug; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.
    Ondocin PT; Narsipur SS
    Nephrology (Carlton); 2006 Dec; 11(6):497-501. PubMed ID: 17199786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.